Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies: A Large Cancer Center Experience Using clonoSEQ - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34343238/

doi: 10.5858/arpa.2020-0457-OA. Online ahead of print. 1 From Hematopathology and Laboratory Medicine (Hussaini), Moffitt Cancer Center, Tampa, Florida. 2 Medical Affairs, Adaptive Biotechnologies, Seattle, Washington (Srivastava, Lee). 3 Blood and...

Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34432864/

The Bcl-2 inhibitor venetoclax has yielded exceptional clinical responses in chronic lymphocytic leukemia (CLL). However, de novo resistance can result in failure to achieve negative minimal residual disease and predicts...

Clinical actionability of measurable residual disease (MRD) assessment in the management of patients with hematologic malignancies: a case-based monograph - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/33843875/

New treatments for hematologic malignancies have led to outcomes that are outpacing the ability of traditional measures of response to accurately capture a patient's depth of response and risk of...